Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September.

Presentation Details:

Event: 2022 Wells Fargo Healthcare Conference Location: Boston, MA Date/Time: Thursday, September 8, 2022, at 1:20 PM ET Format: Fireside Chat

Event: H.C. Wainwright 24th Annual Global Investment Conference Location: New York, NY Date/Time: Tuesday, September 13, 2022, at 11:30 AM ET Format: Podium Presentation

Event: Morgan Stanley 20th Annual Global Healthcare Conference Location: New York, NY Date/Time: Wednesday, September 14, 2022, at 9:10 AM ET Format: Fireside Chat

Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005005/en/

Investor Contact Gitanjali Jain Vice President, Investor Relations and External Affairs 650-269-7523 [e-mail] Media Contact Liza Sullivan Argot Partners 212-600-1902 [e-mail]